Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Gilead Sciences : Kevin Young CBE, Gilead's Chief Operating Officer, to Retire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 06:02pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- Gilead Sciences, Inc. (Nasdaq: GILD) announced that Kevin Young CBE, Chief Operating Officer, plans to retire, effective early 2018. Mr. Young will remain with Gilead through the first quarter of next year and in an advisory capacity thereafter (see also Pharmaceutical Companies).

Mr. Young joined Gilead in 2004 to lead the company's worldwide commercial operations. He oversaw the introduction of multiple new products, including the first single tablet regimens for HIV and the first oral direct acting antiviral regimens for chronic hepatitis C. In 2014, Mr. Young retired from his full-time role and served as a senior advisor to Gilead until 2016, when he returned to assume the role of Chief Operating Officer. Prior to Gilead, he spent more than 20 years in the biopharmaceutical industry, first with ICI Pharmaceuticals and subsequently with Amgen. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise Physiology from Liverpool and Nottingham, England. In 2011, he was appointed a Commander of The British Empire, one of Great Britain's highest civilian honors, in recognition of his "services to the healthcare and pharmaceutical industries."

"Since Kevin joined Gilead in 2004, he has worked tirelessly to build Gilead's commercial success across numerous therapeutic areas and geographies," said John Martin, PhD, Executive Chairman. "Together with the Board of Directors, I am grateful that he came out of semi-retirement in May 2016 to strengthen Gilead and help establish the strategy and execute on plans for our next phase of growth in cell therapy."

"Kevin has had an impact on Gilead - and by extension on the field of medicine and the lives of patients - that is seldom seen," said John Milligan, PhD, President and Chief Executive Officer. "Those who have had the opportunity to work alongside Kevin know that he possesses both a deep commitment to his work and unparalleled leadership abilities. I am delighted that he will be helping us manage through a period of change over the next several months and I am deeply grateful to Kevin for his contributions to Gilead and to the lives of millions of people around the world." About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Keywords for this news article include: Pharmaceutical Companies, Biopharmaceuticals, Drugs and Therapies, Gilead Sciences Inc..

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
10:45pGILEAD SCIENCES : to Slice List Prices of Liver Drugs -- 2nd Update
DJ
10:11pGILEAD SCIENCES : to Slice List Prices of Liver Drugs -- Update
DJ
09:56pGILEAD SCIENCES : to Slice List Prices of Liver Drugs
DJ
03:19pGILEAD SCIENCES : Subsidiary to Launch Authorized Generics to Treat HCV
PU
02:33pGILEAD SCIENCES : Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuv..
BU
09/20GILEAD SCIENCES' : Trademark Application for "WILKARTI" Filed
AQ
09/20GILEAD SCIENCES : Trademark Application for "CAARTUVY" Filed by Gilead Sciences
AQ
09/20GILEAD SCIENCES' : Trademark Application for "TUCAARTI" Filed
AQ
09/20GILEAD SCIENCES : Researchers Submit Patent Application, "Inhibitors Of Bruton'S..
AQ
09/20GILEAD SCIENCES : An Application for the Trademark "WILKARTA" Has Been Filed by ..
AQ
More news
News from SeekingAlpha
04:02pExpress Scripts taking credit for Gilead's planned launch of generic HCV meds 
12:00pEXPECTED VALUE INVESTING : Diving Deeper On Conatus 
08:42aGilead to launch generic versions of Epclusa and Harvoni 
09/21Feds looking into free services from drug makers - WSJ 
09/21What's Next For Gilead? 
Financials ($)
Sales 2018 21 377 M
EBIT 2018 11 220 M
Net income 2018 6 650 M
Debt 2018 12 363 M
Yield 2018 3,01%
P/E ratio 2018 14,98
P/E ratio 2019 13,78
EV / Sales 2018 5,16x
EV / Sales 2019 5,12x
Capitalization 97 887 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 88,0 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES5.40%97 887
VERTEX PHARMACEUTICALS20.17%46 021
REGENERON PHARMACEUTICALS3.81%41 426
NEUROCRINE BIOSCIENCES, INC.54.17%10 822
GENMAB2.04%10 170
SAREPTA THERAPEUTICS INC165.26%9 806